Sunday 19 February 2017 | The one stop source for free breaking news, expert analysis, and videos on AIM and LSE listed shares
Concepta (CPT) has announced a deal that will enhance its fertility product MyLotus with an added stress test. Being stressed out can be a real issue when a chap is trying to get his Mrs up the duff.
Concepta (CPT) has announced that it has secured ISO13485 accreditation which is a key step in attaining its CE marking for its 'myLotus' product for unexplained infertility.
I sat down with Adam Reynolds, the shellmeister today and recorded a string of podcasts. This one is on Concepta (CPT) a stock we own. The shares are 16p-17p. IMHO they should be closer to 30p. The next six months will see masses of news and real, material, sales and that will, I'm sure, drive a real re-rating of the shares. Listen to what Adam says...
Fresh from opening manufacturing facilities in China in late September, Concepta (CPTA) has announced that it has taken on a 10 year lease on a site in Doncaster in the grim North of England to manufacture in the UK. It will be cheap up there.
Concepta (CPT) has announced that it has issued 464,674 shares following the exercise of warrants - something we warned you about last week. That brings in £34,851 which is frankly neither here not there. Around 10% of that cash came from the exercise of warrants by FIML and my pension fund. Neither are selling at anything like this price although the shares are well up on a 14p offer share tip.
We tipped these shares at a 12p offer - they are now 19.5p-21p but hang on tight. We aim to be selling at 25p+ very soon. But before then an urgent reminder for long term holders: warrants! Deadline 6 October.
Concepta (CPT) has announced that it has signed a deal with a Chinese company, Huanzhong Biotech Limited ( HZ) to to assemble and package Concepta's 'My Lotus' fertility product. My Lotus already has regulatory clearance and so this paves the way for a launch very soon indeed.
Hello Share Squaddies. May I bring to your attention another medical outfit which has a very encouraging market to have a go at. The firm is Concepta (CPT) and it has produced something it calls MyLotus. These are clever devices which test fertility in women, as well as being an indicator of pregnancy.
Concepta (CPT) the latest Adam Reynolds healthcare RTO on AIM has announced interim result which are pretty academic. The company is a developer of a platform and suite of products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility.
Investment Case: The AIM admission of Concepta (CPT) a couple of weeks ago was through a reverse takeover of shellmeister (Adam Reynolds)-saved Frontier Resources International (FRI). We backed Reynolds when he became involved in Frontier, but despite his track-record, then was clearly somewhat speculative as we awaited a deal to be delivered. Now it has and it looks like Reynolds has delivered another promising one…
Frontier Resources (FRI) is no more. It is now Concepta (CPT), new shares for the RTO, open offer and placing have been issued and the shares have undergone a 250-1 consolidation.